Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies

Daratumumab has proven to be highly efficacious for relapsed and refractory multiple myeloma (MM) and has recently been approved in the frontline setting for MM patients ineligible for transplantation. In the future, expanded indications are possible for daratumumab and other anti-CD38 monoclonal an...

Descripción completa

Detalles Bibliográficos
Autores principales: Lancman, Guido, Arinsburg, Suzanne, Jhang, Jeffrey, Cho, Hearn Jay, Jagannath, Sundar, Madduri, Deepu, Parekh, Samir, Richter, Joshua, Chari, Ajai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249335/
https://www.ncbi.nlm.nih.gov/pubmed/30498492
http://dx.doi.org/10.3389/fimmu.2018.02616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249335/
https://www.ncbi.nlm.nih.gov/pubmed/30498492
http://dx.doi.org/10.3389/fimmu.2018.02616

Ejemplares similares